24 publications
Name | Date | Type | Actions |
---|---|---|---|
2020 calendar of financial communication December 16, 2019 (Lure, France) - Vetoquinol published its calendar of financial communication for 2020. |
Agenda | ||
Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China. |
Public releases | ||
Q3 2019 sales: €100.2 million (Up 11.0%) The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year. |
Public releases | ||
First half 2019 results At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements. |
Public releases | ||
Vetoquinol announces a new milestone in its industrial strategy Vetoquinol, a leading global animal health player, today announces a plan to reorganize its production facilities in Europe. This decision is in line with the Group’s strategy of streamlining operations in order to improve its response to customer needs, whether vets, breeders or pet owners. |
Public releases | ||
Combined ordinary and extraordinary general meeting May 21, 2019 The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin. |
Public releases | ||
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2018 (french version) The registration document of Vetoquinol relative to fiscal year 2018, including the annual financial report relative to fiscal year 2018, was filed with the Autorité des marchés financiers (“the AMF”) on April 29, 2019.
|
Public releases | ||
Q1 2019 sales: €90.9 million (up 3.7%) Vetoquinol Group sales for Q1 2019 amounted to €90.9 million, up 2.3% at constant exchange rates and up 3.7% as reportedfrom the same period last year. |
Public releases | ||
Vetoquinol finalizes acquisition of Clarion Biociencias in Brazil Lure (France), April 16, 2019 - Vetoquinol today confirms the completion of its acquisition of Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.
|
Public releases | ||
Vetoquinol signs agreement to acquire Clarion Biociênciasin Brazil On April 3rd, Vetoquinol signed an agreement to acquire Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás. |
Public releases | ||
Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%) At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements. |
Public releases | ||
2018 sales: up 3.2% to €367.9 million 9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES
|
Public releases | ||
Information relative au code de gouvernance Lors de la réunion du Conseil d’administration du 16 décembre 2014, les administrateurs ont adopté le code de gouvernance Middlenext. Depuis 2008, Vétoquinol se référait au code AFEP-MEDEF. |
Public releases | ||
Information relative au Code de Gouvernance (french) Lors de la réunion du Conseil d’administration du 16 décembre 2014, les |
Public releases | ||
20145 calendar of financial communication December 15, 2014 (Lure, France) – Vétoquinol published its calendar of financial communication for 2015. |
Agenda | ||
Q3 2014 sales up 11.0% The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates). |
Public releases | ||
Solid growth in Q2 2014: 8.8% first half net income up 4.2% At its July 30, 2014 meeting, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first six months of 2014. |
Public releases | ||
Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction. |
Public releases | ||
Reference products up 2.2% in Q1 2014 Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012. |
Public releases | ||
Vétoquinol is eligible for new PEA-PME funds Lure (France), April 2, 2014 – Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME |
Public releases | ||
2013 growth driven by reference products Lure (France), March 12, 2014 – At its March 11, 2014 meeting, the Vétoquinol SA board of directors reviewed the Group results and approved the 2013 financial statements. |
Public releases | ||
Vétoquinol to acquire the animal health business of Bioniche Life Sciences Inc. LURE, FRANCE and BELLEVILLE, ONTARIO, CANADA, February 27, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche’s Animal Health business for the cash purchase price of CAD$61 million. |
Public releases | ||
7.8% organic growth in Q4 2013 The Vétoquinol Group posted Q4 2013 sales of €80.1 million, up +7.8% like for like from Q4 2012. |
Public releases | ||
Jean-Yves RAVINET appointed Group Chief Operating Officer Lure (France), January 7, 2014 – The Vétoquinol Group announces the appointment of Jean-Yves Ravinet as Group Chief Operating Officer. |
Public releases |